Bayer Animal Health has announced that it has been given marketing authorisation in Europe for Neptra (florfenicol, terbinafine hydrochloride, mometasone furoate), a new treatment for canine otitis externa which requires just one dose, administered by the veterinary surgeon.

Neptra has been approved for the treatment of acute canine otitis externa or acute exacerbations of recurrent otitis caused by mixed infections of susceptible strains of bacteria sensitive to florfenicol (Staphylococcus pseudintermedius) and fungi sensitive to terbinafine (Malassezia pachydermatis), by the European Commission.

Mario Andreoli, Head of Marketing at Bayer Animal Health, said: "Otitis externa is a common disease in dogs and a leading cause why owners take their dog to a veterinarian.

"Neptra offers a key advantage, unlike competing products, it requires just one dose, administered by the veterinarian in the practice."

No at-home applications by the dog owner are required. The treatment stays in the hands of the vet who has full control over compliance.

Mario added: "With Neptra we provide a high-quality veterinary treatment that is convenient for the dog owner and ensures the well-being of dogs with a proper, effective application."

VetSurgeon understands the new product will be available in the UK in January 2020.

Whilst you're here, take a moment to see our latest job opportunities for vet nurses.